These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 32537913)

  • 1. A Bayesian approach in design and analysis of pediatric cancer clinical trials.
    Ye J; Reaman G; De Claro RA; Sridhara R
    Pharm Stat; 2020 Nov; 19(6):814-826. PubMed ID: 32537913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian adaptive design for pediatric clinical trials incorporating a community of prior beliefs.
    Wang Y; Travis J; Gajewski B
    BMC Med Res Methodol; 2022 Apr; 22(1):118. PubMed ID: 35448963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empirical profile Bayesian estimation for extrapolation of historical adult data to pediatric drug development.
    Wu Y; Hui J; Deng Q
    Pharm Stat; 2020 Nov; 19(6):787-802. PubMed ID: 32573051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancing pediatric clinical trial feasibility through the use of Bayesian statistics.
    Huff RA; Maca JD; Puri M; Seltzer EW
    Pediatr Res; 2017 Nov; 82(5):814-821. PubMed ID: 28700566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safety.
    Teramukai S; Daimon T; Zohar S
    Stat Med; 2015 Sep; 34(22):3029-39. PubMed ID: 26038148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statistical modeling for Bayesian extrapolation of adult clinical trial information in pediatric drug evaluation.
    Gamalo-Siebers M; Savic J; Basu C; Zhao X; Gopalakrishnan M; Gao A; Song G; Baygani S; Thompson L; Xia HA; Price K; Tiwari R; Carlin BP
    Pharm Stat; 2017 Jul; 16(4):232-249. PubMed ID: 28448684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TITE-BOIN-ET: Time-to-event Bayesian optimal interval design to accelerate dose-finding based on both efficacy and toxicity outcomes.
    Takeda K; Morita S; Taguri M
    Pharm Stat; 2020 May; 19(3):335-349. PubMed ID: 31829517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Bayesian Hybrid Adaptive Randomisation Design for Clinical Trials with Survival Outcomes.
    Moatti M; Chevret S; Zohar S; Rosenberger WF
    Methods Inf Med; 2016; 55(1):4-13. PubMed ID: 26404511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bayesian and frequentist approaches to sequential monitoring for futility in oncology basket trials: A comparison of Simon's two-stage design and Bayesian predictive probability monitoring with information sharing across baskets.
    Kaizer A; Zabor E; Nie L; Hobbs B
    PLoS One; 2022; 17(8):e0272367. PubMed ID: 35917296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incorporating Innovative Techniques Toward Extrapolation and Efficient Pediatric Drug Development.
    Gamalo-Siebers M; Hampson L; Kordy K; Weber S; Nelson RM; Portman R
    Ther Innov Regul Sci; 2019 Sep; 53(5):567-578. PubMed ID: 31084211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bayesian design using adult data to augment pediatric trials.
    Schoenfeld DA; Hui Zheng ; Finkelstein DM
    Clin Trials; 2009 Aug; 6(4):297-304. PubMed ID: 19667026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bayesian statistical methods in public health and medicine.
    Etzioni RD; Kadane JB
    Annu Rev Public Health; 1995; 16():23-41. PubMed ID: 7639872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A structured framework for adaptively incorporating external evidence in sequentially monitored clinical trials.
    Kwiatkowski E; Andraca-Carrera E; Soukup M; Psioda MA
    J Biopharm Stat; 2022 May; 32(3):474-495. PubMed ID: 35797378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bayesian approach to noninferiority trials for proportions.
    Gamalo MA; Wu R; Tiwari RC
    J Biopharm Stat; 2011 Sep; 21(5):902-19. PubMed ID: 21830922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leveraging historical data into oncology development programs: Two case studies of phase 2 Bayesian augmented control trial designs.
    Smith CL; Thomas Z; Enas N; Thorn K; Lahn M; Benhadji K; Cleverly A
    Pharm Stat; 2020 May; 19(3):276-290. PubMed ID: 31903699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unified approach for extrapolation and bridging of adult information in early-phase dose-finding paediatric studies.
    Petit C; Samson A; Morita S; Ursino M; Guedj J; Jullien V; Comets E; Zohar S
    Stat Methods Med Res; 2018 Jun; 27(6):1860-1877. PubMed ID: 27705884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A hybrid Bayesian adaptive design for dose response trials.
    Chang M; Chow SC
    J Biopharm Stat; 2005; 15(4):677-91. PubMed ID: 16022172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bayesian clinical trials at The University of Texas MD Anderson Cancer Center: An update.
    Tidwell RSS; Peng SA; Chen M; Liu DD; Yuan Y; Lee JJ
    Clin Trials; 2019 Dec; 16(6):645-656. PubMed ID: 31450957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic/pharmacodynamic data extrapolation models for improved pediatric efficacy and toxicity estimation, with application to secondary hyperparathyroidism.
    Basu C; Ma X; Mo M; Xia HA; Brundage R; Al-Kofahi M; Carlin BP
    Pharm Stat; 2020 Nov; 19(6):882-896. PubMed ID: 32648333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.